CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
CD30, a member of the TNF receptor superfamily, is selectively expressed on a subset of activated lymphocytes and on malignant cells of certain lymphomas, such as classical Hodgkin Lymphoma (cHL), where it activates critical bystander cells in the tumor microenvironment. Therefore, it is not surpris...
Main Authors: | Liudmila Lobastova, Marcus Lettau, Felix Babatz, Thais Dolzany de Oliveira, Phuong-Hien Nguyen, Bianca Alves Pauletti, Astrid C. Schauss, Horst Dürkop, Ottmar Janssen, Adriana F. Paes Leme, Michael Hallek, Hinrich P. Hansen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.698503/full |
Similar Items
-
Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma
by: Hinrich P. Hansen, et al.
Published: (2020-03-01) -
Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView
by: Daniel Bachurski, et al.
Published: (2019-12-01) -
Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
by: Philipp Koehler, et al.
Published: (2012-01-01) -
Testing sensitivity to cd30 targeting via brentuximab vedotin in multiple myeloma
by: E. La Spina, et al.
Published: (2020-09-01) -
CD30 - the head of TNF-family… or a successful story of brentuximab vedotin
by: Popović Lazar, et al.
Published: (2013-01-01)